Medici List

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company developing cytisinicline to treat nicotine dependence (primarily smoking and vaping cessation) with principal offices in Bothell, WA and Vancouver, BC.

The Fund is a newly formed, permanent, non-exchange-traded BDC that seeks current income and some capital appreciation by investing primarily in directly originated senior secured first‑lien loans to privately held U.S. middle‑market companies, with limited exposure to second‑lien and mezzanine debt, equity‑like instruments, and opportunistic liquid credits, managed through a structured relationship with Audax Private Debt and its affiliates.

Andretti Acquisition Corp is a Cayman Islands special purpose acquisition company formed May 21, 2024 to effect an initial business combination, raised $230.0M in an IPO plus $7.6M in a private placement, holds trust assets for a target transaction, and has no operating revenues to date.

A private Delaware limited liability company formed in 2021 that operates as a REIT-focused investment fund targeting U.S. commercial real estate debt and related assets, managed by an SEC-registered investment manager.

Absci is a clinical-stage biopharmaceutical company that uses an AI-native Integrated Drug Creation platform to design and rapidly validate antibody therapeutics and advances internal programs while generating partner-derived revenue.

Clinical-stage biopharmaceutical company developing oral small-molecule TAS2R agonists (lead ARD-101) to stimulate endogenous gut hormones and suppress hunger for metabolic diseases.

Consumer products company that owns and markets multiple consumer brands and primarily sells online through e-commerce marketplaces (predominantly Amazon US) and direct-to-consumer websites.

Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), a high-affinity anti-IL-1β monoclonal antibody primarily for hidradenitis suppurativa, currently in a Phase 2 LOTUS trial with topline data expected in Q2 2026 and no approved products to date.

Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing curative therapies for chronic hepatitis B, advancing RNAi therapeutic AB-729 (imdusiran) and oral PD-L1 inhibitor AB-101 while monetizing LNP/IP through collaborations and licensing.

Ambarella designs and sells low-power system-on-chip processors and software for edge and physical AI, enabling on-device multi-modal sensor fusion and inference for IoT, automotive, robotics, and edge computing applications.

Ashford Hospitality Trust, Inc. is a real estate investment trust that owns and finances a portfolio of upscale and upper-upscale full-service hotels in the U.S., contracting hotel operations to third-party managers and relying on Ashford LLC for advisory and asset-management services.

Pre-commercial low-carbon energy company developing and commercializing licensed and proprietary pyrolysis and upgrading technologies to convert waste plastics and biomass into refinery-compatible renewable fuels and chemical feedstocks, with development hub planned at Cedar Port (Baytown, TX) and non-material legacy oil and gas operations.